Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 4 selected

Guidance programme

Showing 1 to 6 of 6

TitleReference numberPublishedLast updated
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA563
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemiaTA561
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanomaTA562
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)TA560
Darvadstrocel for treating complex perianal fistulas in Crohn's diseaseTA556
Regorafenib for previously treated advanced hepatocellular carcinomaTA555

Results per page

  1. 10
  2. 25
  3. 50
  4. All